Hipertene

Quick links to important sections

Hipertene

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hipertene

Hipertene is a branded, prescription-only (Rx) medication used primarily for the treatment of essential hypertension (high blood pressure). It is an oral tablet utilizing the active drug Imidapril as its main component. The drug belongs to a class of medications known as Angiotensin-Converting Enzyme (ACE) Inhibitors.


Quick Facts

Property Description
Active ingredient Imidapril (Hydrochloride)
Form Oral tablet
Pharmacological class ACE Inhibitor
Common use Essential hypertension
Status Prescription (Rx) drug

Mechanism and Medical Use

Imidapril is classified pharmacologically as a prodrug, meaning it is inactive when swallowed and becomes the potent therapeutic agent, Imidaprilat, once metabolized by the liver. This process is a key element of its design, supporting its effective use in managing high blood pressure.

ACE inhibitors work by helping to relax and widen blood vessels throughout the body, which, in turn, allows blood to flow more easily and lowers the overall pressure inside the arteries. The clinical efficacy of Imidapril in reducing blood pressure and managing mild to severe hypertension is established in cardiovascular therapy.

Furthermore, Imidapril possesses recognized therapeutic properties that extend beyond the treatment of hypertension, including its use in the management of specific cases of congestive heart failure. This broad medical utility supports its role as a medication for the sustained, long-term management of cardiovascular risk.

Regulatory References

  1. EMA ACE Inhibitors Overview

What side effects are possible with Hipertene?

Possible side effects and safety information

The safety profile of Hipertene (Imidapril) is organized according to standardized regulatory frameworks, classifying possible adverse reactions by frequency and the organ systems affected, as documented in official prescribing information.


Documented Adverse Reaction Categories

Adverse effects are categorized based on their documented frequency in clinical studies. Common reactions reported include dry cough, dizziness, headache, and general fatigue or weakness. Other reactions involve the Gastrointestinal System (e.g., nausea, vomiting, diarrhea) and the Nervous System (e.g., lightheadedness).

Reactions involving the Cardiovascular System may include symptomatic hypotension (low blood pressure), which is often noted to be more likely to occur after the first dose or upon the initiation of therapy.


Serious Adverse Reactions and Safety Constraints

Official regulatory documents detail serious adverse reactions that require specific attention. The most critical risk is Angioedema, which is rapid swelling involving the face, lips, tongue, glottis, and/or larynx, carrying a risk of airway obstruction. While this reaction can occur early, its possibility is documented throughout treatment.

Safety constraints also address specific populations. Hipertene is formally contraindicated for use during the second and third trimesters of pregnancy due to the serious, documented risk of fetal injury and death (fetal toxicity). Additionally, caution and close patient monitoring are required for individuals with existing renal impairment due to the documented risk of changes in renal function, including acute renal failure in susceptible cases.

Other documented regulatory concerns include the risk of Hyperkalemia (elevated blood potassium levels) and potential impairment of activities such as driving or operating machinery due to the possibility of dizziness.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section describes officially documented overdose manifestations and mandated emergency actions for Imidapril, the active ingredient in Hipertene, as specified in government regulatory documents.

Feature Official Regulatory Statements for Imidapril/ACE Inhibitor Overdose
Documented overdose presentations Severe hypotension (profound low blood pressure), circulatory shock, acute renal failure, stupor, bradycardia or tachycardia, electrolyte disturbances, dizziness, and apathy.
Physiological systems affected Cardiovascular, Renal, Central Nervous System (CNS), and Electrolyte systems.
Population-specific overdose notes Patients with pre-existing renal impairment face an increased risk of developing acute renal failure if severe hypotension occurs.
Required emergency actions The patient should be placed in the supine position to manage excessive hypotension. Treatment involves administering intravenous (IV) volume expansion (e.g., normal saline) and other supportive measures.

When Immediate Medical Help is Required (Label-Derived Phrasing Only):

Seek immediate medical attention or contact emergency services immediately upon suspicion of overdose, especially if severe hypotension or signs of circulatory shock are present. As no specific antidote is known, the management provided is symptomatic and supportive, focusing on maintaining vital signs. Regulatory documents mandate close monitoring of vital signs, serum electrolytes, and renal function until the patient is clinically stable. The severity of the overdose is often classified based on the resulting level of hypotension and associated systemic compromise.

Therapeutic Uses of Hipertene

Hipertene (Imidapril) is a foundational therapeutic agent generally used for managing chronic conditions that involve the cardiovascular and renal systems. It generally supports the maintenance of long-term stability and may assist in managing the progression of chronic disease markers. The drug's profile makes it relevant for managing these complex conditions.

The primary use of Hipertene is in the sustained management of essential hypertension (high blood pressure). It is also commonly used to provide supportive relief for managing chronic heart failure and addressing specific markers of diabetic nephropathy. This means the medication may assist with managing symptoms linked to organ-specific functional stress and supports the symptomatic management of chronic cardiac conditions.

“This medication is applied in addressing symptoms linked to organ-specific functional stress, providing supportive relief when symptoms interfere with routine activities.”


Quick Fact: Supports Management of Systemic Imbalance

Hipertene is commonly used in clinical settings where long-term management of heightened physiological activity (high blood pressure) is appropriate. It plays a role in managing symptoms that create noticeable functional strain on the heart and kidneys, thereby assisting with maintaining functional stability.

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility requirements for Hipertene (Imidapril) based on governmental regulatory guidelines. The drug is primarily authorized for use in adult patients for the sustained management of essential hypertension.


Absolute Contraindications

Hipertene is strictly contraindicated (must not be used) for the following populations and conditions:

  • Patients with a history of angioedema (severe swelling) related to any previous ACE inhibitor treatment, or with hereditary/idiopathic angioedema.
  • Women who are pregnant (especially the second and third trimesters) or breastfeeding.
  • Individuals with hypersensitivity to Imidapril or any other ACE inhibitor.
  • Patients with Renovascular Hypertension or severe renal impairment (e.g., creatinine clearance below 30 mL/min).
  • Patients receiving certain other medications, such as sacubitril/valsartan.

Restricted Use and Special Populations

Population / Condition Regulatory Classification
Pediatric Patients (Children/Adolescents) Use is not established or not recommended due to insufficient data.
Older Adults (Geriatric) Use requires caution and a lower initial dose is generally advised.
Impaired Renal Function Requires caution; dose adjustment is needed for moderate impairment.
Severe Hepatic Impairment Contraindicated or restricted; use requires specialist monitoring.
Aortic/Mitral Stenosis Use requires caution due to specific cardiovascular risk.

These constraints ensure the drug is used only in patient populations where its eligibility is formally documented by regulatory authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific drug and substance combinations that interact with Hipertene (Imidapril), primarily through pharmacodynamic and select pharmacokinetic mechanisms.

Interaction Type Interacting Agent (Class/Specific) Regulatory Outcome / Restriction
Contraindicated Sacubitril/Valsartan Mandatory 36-hour wash-out period required between switching to or from Imidapril to avoid severe angioedema risk.
Contraindicated Aliskiren Prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/ min/1.73 m^2).
Pharmacodynamic Potassium-Sparing Diuretics, Potassium Supplements, Potassium-Rich Salt Substitutes Increased risk of hyperkalemia (elevated serum potassium levels).
Pharmacodynamic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Potential for loss of antihypertensive effect and risk of renal function deterioration.
Pharmacodynamic mTOR Inhibitors, DPP-4 Inhibitors Increased risk of angioedema (swelling).
Pharmacokinetic Lithium Imidapril reduces the renal clearance of Lithium, leading to increased serum concentration and potential toxicity.
Food/Substance Food (high-fat meal) Documented to decrease the bioavailability of Imidapril and its active metabolite, Imidaprilat.

These interactions necessitate careful assessment, as they can enhance hypotensive effects when combined with other antihypertensive agents or lead to severe consequences, such as anaphylactoid reactions with certain high-flux dialysis membranes. All interaction information is based on the specific conditions and restrictions detailed in government drug labels.

Mechanism of Action

How Hipertene Works (Mechanism of Action)

Hipertene's activity stems from its active metabolite, Imidaprilat, which engages a two-part mechanism focused on the modulation of key humoral pathways that regulate vascular tension and fluid volume. The drug acts exclusively within domains involving enzyme-mediated signaling to modulate signaling within key regulatory systems.


Inhibition of the Angiotensin-Converting Enzyme (ACE)

The primary action involves competitive inhibition of the ACE enzyme. This inhibitory step blocks the conversion of Angiotensin I to the vasoconstrictor, Angiotensin II, thereby interfering with a primary cascade that regulates vascular tension. The molecular blockade results in a reduction in Total Peripheral Resistance (TPR).


Modulation of the RAAS and Fluid Homeostasis

Interrupting the Renin-Angiotensin-Aldosterone System (RAAS) cascade results in a significant reduction in Angiotensin II, which in turn decreases the release of Aldosterone from the adrenal cortex. This hormonal shift adjusts the balance toward natriuresis (sodium and water excretion), resulting in a reduction in the overall circulating blood volume.


Potentiation of Endogenous Vasodilation

Simultaneously, the ACE enzyme is identical to Kininase II, an enzyme that degrades the natural vasodilator, Bradykinin. By inhibiting Kininase II, Imidaprilat slows the breakdown of Bradykinin, allowing its levels to increase. The potentiation of this intrinsic vasodilator pathway contributes to the relaxation of vascular smooth muscle, acting in parallel with the effects of reduced Angiotensin II signaling.

Dosage and Administration Information

Hipertene (Imidapril) is an oral tablet intended for long-term, chronic management, administered on a once-daily schedule. The usage protocol is defined by clinical practice guidelines, emphasizing careful dose determination and specific intake conditions, and it must be taken as prescribed.


Administration Protocol

The administration route for Hipertene is exclusively oral. Dosage is initiated through a titration process, beginning with a low starting dose that is gradually increased over time until the stable maintenance dose is achieved.

Instruction Standard Protocol
Dosing Frequency Once daily
Typical Starting Dose 5 mg once daily (standard adult)
Maximum Daily Dose 20 mg once daily
Timing Administered with water. Some regional labels specify taking the tablet 15 minutes before meals (preprandial).

Dose Adjustments and Special Use

Standard medical protocols outline adjustments to the regimen based on specific patient factors.

  • Older Adults and Impaired Function: For patients aged 65 and older, or those with known renal or hepatic impairment, a lower initial dose of 2.5 mg once daily is typically required. The maximum recommended dose in these cases is often restricted to 10 mg.
  • Missed Dose: If a dose is missed, instructions advise against taking a double dose. The user should skip the missed dose and resume the next scheduled dose at the usual time.

These guidelines establish the procedural structure for using the medicine as part of a supervised treatment plan.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hipertene

This section provides a factual summary of the structural research that has studied the evidence for Hipertene (Imidapril), detailing what outcomes were studied and what remains uncertain. The information presented here describes group patterns observed in research and does not provide individual predictions or medical advice.


Evidence for Use in Essential Hypertension

Research has studied Hipertene's use in essential hypertension (high blood pressure) through a body of evidence that includes core Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies primarily involved adults with mild to moderate high blood pressure. Researchers monitored outcomes related to systemic or functional imbalance, specifically focusing on the change measured in Systolic and Diastolic Blood Pressure (SBP/DBP) readings.

Analysis of the overall evidence landscape for this drug class has described patterns related to major cardiovascular outcomes in studies where a comparison group was used. Data are still emerging for certain long-term comparisons specific to Imidapril, and scientific discussion continues regarding the optimal intensity of blood pressure control needed for diverse patient groups.


Evidence for Use in Chronic Heart Failure

The evidence for Hipertene in chronic heart failure (CHF) was evaluated in a structure of RCTs and meta-analyses, often examining the entire ACE inhibitor drug class. The studies explored adults diagnosed with CHF, frequently those with reduced ejection fraction.

Researchers examined a variety of outcomes, including objective measures of heart function like the Left Ventricular Ejection Fraction (LVEF), as well as measures reflecting daily functioning or activity level. Clinical trials also monitored major events like the rate of hospitalization for heart failure exacerbations and all-cause mortality.


Long-Term Research and Durability of Effect

Hipertene was studied for extended observation periods over defined time intervals. Follow-up durations were limited in specific comparative studies when focusing solely on initial blood pressure response. However, evidence for the drug class as a whole includes observational settings evaluating daily-life functioning over several years.

Key Limitations and Areas of Uncertainty

The evidence quality varies across studies, and sample sizes were modest in some of the specific research focusing on the renal and heart failure indications for Imidapril, meaning subgroup findings are uncertain and require additional research to clarify. Long-term effects are not fully established for certain specific clinical outcomes when comparing Imidapril directly against all newer standard-of-care treatments in recent trials; comparative evidence is lacking in some head-to-head scenarios.

Frequently Asked Questions (FAQ)

Common questions about Hipertene (FAQ)


Q: How quickly does Hipertene typically start working?

According to the official product information, the initial form of the medicine, Imidapril, reaches its highest level in the bloodstream about two hours after being taken. Its active component, Imidaprilat, reaches peak levels around seven hours. While the drug is active soon after administration, achieving the full and stable therapeutic benefit for blood pressure reduction may require several weeks of continuous therapy.


Q: Is it true that Hipertene can cause dizziness?

Yes, dizziness is one of the commonly reported adverse reactions documented in the official prescribing information for Hipertene. This feeling may be experienced more noticeably when you first start taking the medicine or when the amount you take is being adjusted.


Q: Does Hipertene interact with common over-the-counter pain relievers?

Official documents describe that medicines belonging to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class can interact with Hipertene. This interaction may potentially lessen Hipertene's blood pressure-lowering effect and can increase the risk of changes in kidney function. Therefore, awareness of this potential interaction is advised when considering the use of common pain relievers in this class.


Q: What is the expected timeline for seeing the full benefits of Hipertene?

While the medicine begins its action after the first administration, the achievement of the full, desired therapeutic effect, specifically for long-term blood pressure control, may require several weeks of continued therapy. This timeline is consistent with the drug’s role in sustained, chronic management.


Q: What should I do if I experience an unusual side effect while on Hipertene?

Official guidance instructs patients to immediately report any signs or symptoms that could suggest a serious side effect, such as swelling of the face, tongue, or difficulty breathing, and to seek professional help. For other non-urgent or unusual effects, consulting a healthcare provider for clarification is the documented practice.


Q: Does taking Hipertene affect driving or operating machinery?

Official documents state that a person's ability to drive or operate complex machinery may be impaired because Hipertene can cause adverse effects like dizziness and fatigue. This caution is often highlighted, especially when starting treatment or when the dosage is being changed.


Q: What are the main things that determine who is eligible to take Hipertene?

Eligibility to take the medicine is determined by regulatory-defined factors. This includes having a documented indication, such as essential hypertension, and the absence of specific conditions. Absolute contraindications include a history of angioedema related to ACE inhibitors, pregnancy, or severe kidney or liver impairment.


Q: Is it normal to feel tired when first starting Hipertene?

Fatigue or general weakness is listed in official safety documents as a common adverse reaction for this medicine. Adverse effects are often noticed when initiating therapy, according to official documents.


Q: Are there any foods or drinks to avoid while taking Hipertene?

Official documents specifically advise that consuming a high-fat meal can reduce the absorption of the active substance. For other foods or drinks, specific restrictions are not explicitly detailed in the prescribing information.


Q: What does 'mechanism of action' mean for Hipertene in simple terms?

In simple terms, the medicine works by interfering with an enzyme that has two main effects. First, it blocks the creation of a substance that normally tightens blood vessels, allowing them to relax. Second, it slows down the breakdown of natural body substances that widen blood vessels, helping to keep them relaxed. This combined effect helps to lower blood pressure.


Q: Can children or adolescents use Hipertene?

Official regulatory documents state that the use of Hipertene in pediatric patients (children and adolescents) is either not recommended or not established. This is due to a lack of sufficient data on the safety and effectiveness of the medicine in these specific age groups.


Q: Can I take Hipertene with an empty stomach?

The official instructions specify that the tablet should be taken with water. Some regional labels specifically recommend administration 15 minutes before a meal (preprandial), which highlights the importance of timing relative to food intake for the medicine's optimal absorption.


Q: Is the long-term safety of Hipertene supported by research?

Research has included extended observation periods to study the drug’s long-term durability of effect. However, the official evidence summary notes that the long-term effects on specific clinical outcomes are not fully established when Hipertene is compared directly against all newer standard-of-care treatments.


Q: Can Hipertene cause skin reactions or rashes?

Serious reactions involving swelling (angioedema) of the face, tongue, or throat are documented risks. Additionally, other non-serious allergic reactions involving the skin, such as itching or rash, may be listed as possible adverse effects consistent with the drug class.


Q: Do official sources describe any maximum length of time for taking Hipertene?

The official information describes Hipertene as a medicine intended for the sustained, long-term, and chronic management of high blood pressure. Regulatory documents do not specify a maximum length of time for its continuous use.

How should Hipertene be stored and disposed of?

How to Store and Dispose of Hipertene (Imidapril) Tablets

The storage and disposal instructions for Hipertene tablets are established to maintain the quality of the medicine and ensure public safety.


Required Storage Conditions

Hipertene must be stored away from heat and direct sunlight, and the temperature must not exceed 30 C. The tablets should be protected from moisture and kept in tightly closed containers, as high heat and humidity can cause degradation. Like all prescription medications, it must be kept out of the reach of children.


Disposal Instructions

Unused or expired Hipertene must be disposed of according to local, state, and federal regulations. To ensure proper pharmaceutical waste management, the product should not be released into the environment, and disposal via the sink or toilet is not recommended. Consult a local pharmacy or waste authority for authorized take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hipertene found in:

A-Z Index: